fruquintinib

Phase 1Completed

0 watching 0 views this week💤 Quiet

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Food Effect of Fruquintinib in Health Subjects

Conditions

Food Effect of Fruquintinib in Health Subjects

Trial Timeline

Jun 1, 2012 → Dec 1, 2012

NCT ID

NCT01955304

About fruquintinib

fruquintinib is a phase 1 stage product being developed by HUTCHMED for Food Effect of Fruquintinib in Health Subjects. The current trial status is completed. This product is registered under clinical trial identifier NCT01955304. Target conditions include Food Effect of Fruquintinib in Health Subjects.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (7)

NCT ID	Phase	Status	Start	Completion	Indication
NCT05216354	Phase 1	Completed	Mar 11, 2022	Jun 26, 2023	Renal Impairment
NCT05216367	Phase 1	Completed	Mar 11, 2022	Oct 25, 2022	Hepatic Impairment
NCT03684967	Phase 2	Withdrawn	May 8, 2018	Sep 6, 2019	Lung Cancer
NCT02689752	Phase 1	Completed	Jul 1, 2016	Sep 1, 2016	Healthy
NCT01975077	Phase 1/2	Completed	Dec 1, 2012	Oct 1, 2014	Colorectal Cancer
NCT01955304	Phase 1	Completed	Jun 1, 2012	Dec 1, 2012	Food Effect of Fruquintinib in Health Subjects
NCT01645215	Phase 1	Completed	Jan 1, 2011	Oct 1, 2012	Tumor

Competing Products

17 competing products in Food Effect of Fruquintinib in Health Subjects

See all competitors

Product	Company	Stage	Hype Score
Milademetan Treatment A + Milademetan Treatment B + Milademetan Treatment C	Daiichi Sankyo	Phase 1	33
E7386	Eisai	Phase 1	33
AZD7986, oral solution, 1 to 50 mg/mL + Placebo, oral solution	AstraZeneca	Phase 1	33
Acalabrutinib	AstraZeneca	Phase 2	52
esomeprazole/ASA Fixed Dose Combination (FDC)	AstraZeneca	Phase 1	33
Ligelizumab 120 mg + Ligelizumab 240 mg	Novartis	Phase 3	77
Omalizumab	Novartis	Approved	85
Omalizumab Injection	Roche	Approved	85
Glucopyranosyl Lipid A (GLA) + Sublingual Immuno Therapy (SLIT) Peanut Extract (PE) + Placebo for GLA + Placebo for SLIT PE	Sanofi	Phase 1	32
Dupilumab	Regeneron Pharmaceuticals	Pre-clinical	22
linvoseltamab + dupilumab	Regeneron Pharmaceuticals	Phase 1	32
Dupilumab	Regeneron Pharmaceuticals	Phase 2	51
Sativex + Sativex + Sativex + Sativex	Jazz Pharmaceuticals	Phase 1	30
Volitinib	HUTCHMED	Phase 1	28
Viaskin Milk 150 mcg + Viaskin Milk 300 mcg + Viaskin Milk 500 mcg + Viaskin Placebo	DBV Technologies	Phase 1/2	36
AZD1722 salt tablet + AZD1722 free base tablet + AZD1722 free base tablet + Omeprazole	Ardelyx	Phase 1	28
E. Coli-Encapsulated, Recombinant Modified Peanut Proteins Ara h 1, Ara h 2, and Ara h 3	Allergy Therapeutics	Phase 1	28

Other Products from HUTCHMED

fruquintinib + sintilimab + paclitaxel + doxorubicinPhase 3

fruquintinib + placeboPhase 3

Fruquintinib + PlaceboPhase 3

HMPL-760 + HMPL-760 Placebo + R-GemOxPhase 3

SurufatinibPhase 3